ICON Strategic Solutions provide insights on customised FSP models to enable the most flexible and efficient operating models for Sponsors.
For mid-size pharma, CRO and FSP models may evolve as the company grows. This either/or decision often means switching models by switching suppliers. By harnessing the ‘Embedded Blended’ model, all sponsors can benefit from a synchronised outsourcing strategy.Download the whitepaper
Presenting a unique approach to evolve the traditional local clinical development model in Japan, while lowering costs, improving productivity, and potentially accelerating drug approval timelines.Download the whitepaper
Japan is the third-largest consumer of ethical drugs and the world’s third-largest economy; therefore, it is an important development centre for new medicines. However, there are various cultural and economic challenges in Japan that make it difficult to manage a fixed workforce against a variable portfolio of clinical research.
John Barry and Brian Swindley offer their insights on the options available to pharma companies when delivering their clinical trial portfolios.
This spotlight feature authored by ICON's Barry Balfe examines how pharmaceutical companies are increasing their functional service partnership expenditure at a rapid rate, and the key considerations in selecting and executing the FSP model which are being overlooked.
As the market for outsourcing continues to grow, so too have the types of outsourcing models available to sponsors.
ICON offers a range of FSP models that can be customised to deliver the most efficient operating model for your organisation. We have deployed FSP solutions across all major functions from clinical monitoring and project management through data management, statistical programming and beyond.Read more